Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim resultsSham Mailankody, Shaji Kumar, Myo Htut et al.|Nature Medicine|2023Cited by 239
Insights from Clinical Trials: Evidence-Based Recommendations for Induction Treatment of Newly Diagnosed Transplant-Eligible Multiple MyelomaOlga Lytvynova, Faiz Anwer, Jenna Jwayyed et al.|Antibodies|2024Cited by 4
Evidence-Based Recommendations for Induction Treatment of Newly Diagnosed Transplant-Eligible Multiple Myeloma Patients; A Scoping ReviewOlga Lytvynova, Faiz Anwer, Jenna Jwayyed et al.|Blood|2023Cited by 2
Insights from Clinical Trials: Evidence-Based Recommendations for Induction Treatment of Newly Diagnosed Transplant-Eligible Multiple MyelomaOlga Lytvynova, Faiz Anwer, Jenna Jwayyed et al.|Preprints.org|2024Cited by 2
Management of relapsed refractory multiple myeloma: Evidence-based guide to community oncologistsAli Mushtaq, Faiz Anwer, Asfand Yar Cheema et al.|Blood Reviews|2025Cited by 2